Skip to main content

Advertisement

SpringerLink
Log in

One-year efficacy of adjunctive use of Ripasudil, a rho-kinase inhibitor, in patients with glaucoma inadequately controlled with maximum medical therapy

  • Glaucoma
  • Published:
Graefe's Archive for Clinical and Experimental Ophthalmology Aims and scope Submit manuscript

Abstract

Purpose

The aim of this study was to evaluate the one-year efficacy, ability to lower intraocular pressure, and tolerability of ripasudil, a rho-kinase inhibitor, in patients with glaucoma inadequately controlled with maximum medical therapy.

Methods

This prospective, non-comparative, interventional case-series study included 39 patients with primary open-angle glaucoma inadequately controlled with maximum medical therapy before treatment with ripasudil. Ripasudil was administered twice per day as adjunctive therapy to ongoing glaucoma treatment. The primary endpoint was the degree of intraocular pressure reduction after 12 months of treatment; the secondary endpoints were the incidence of adverse events.

Results

We examined 39 eyes. The intraocular pressure reduction (given as the relative percentage of intraocular pressure reduction) from baseline was −2.6 mmHg (−15.5%; 95% confidence interval, −1.1 to −3.9 mmHg; P < 0.001) after 12 months of treatment. The adverse events were conjunctival hyperemia (all patients), blepharitis (three), allergic conjunctivitis (two), punctate keratitis (two), and ophthalmalgia (one).

Conclusions

Treatment with ripasudil decreased intraocular pressure in patients with glaucoma that was poorly controlled with maximal medical therapy, and it was well-tolerated.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. The AGIS Investigators (2000) The advanced glaucoma intervention study (AGIS): 7 the relationship between control of intraocular pressure and visual field deterioration. Am J Ophthalmol 130:429–440

    Article  Google Scholar 

  2. Kass MA, Heuer DK, Higginbotham EJ, Johnson CA, Keltner JL, Miller JP, Parrish RK 2nd, Wilson MR, Gordon MO (2002) The ocular hypertension treatment study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol (Chicago, Ill : 1960) 120:701–713 discussion 829-730

    Article  Google Scholar 

  3. Musch DC, Gillespie BW, Lichter PR, Niziol LM, Janz NK (2009) Visual field progression in the collaborative initial glaucoma treatment study the impact of treatment and other baseline factors. Ophthalmology 116:200–207. doi:10.1016/j.ophtha.2008.08.051

    Article  PubMed  Google Scholar 

  4. Honjo M, Tanihara H, Inatani M, Kido N, Sawamura T, Yue BY, Narumiya S, Honda Y (2001) Effects of rho-associated protein kinase inhibitor Y-27632 on intraocular pressure and outflow facility. Invest Ophthalmol Vis Sci 42:137–144

    CAS  PubMed  Google Scholar 

  5. Isobe T, Mizuno K, Kaneko Y, Ohta M, Koide T, Tanabe S (2014) Effects of K-115, a rho-kinase inhibitor, on aqueous humor dynamics in rabbits. Curr Eye Res 39:813–822. doi:10.3109/02713683.2013.874444

    Article  CAS  PubMed  Google Scholar 

  6. Kameda T, Inoue T, Inatani M, Fujimoto T, Honjo M, Kasaoka N, Inoue-Mochita M, Yoshimura N, Tanihara H (2012) The effect of rho-associated protein kinase inhibitor on monkey Schlemm’s canal endothelial cells. Invest Ophthalmol Vis Sci 53:3092–3103. doi:10.1167/iovs.11-8018

    Article  CAS  PubMed  Google Scholar 

  7. Rao PV, Deng P, Sasaki Y, Epstein DL (2005) Regulation of myosin light chain phosphorylation in the trabecular meshwork: role in aqueous humour outflow facility. Exp Eye Res 80:197–206. doi:10.1016/j.exer.2004.08.029

    Article  CAS  PubMed  Google Scholar 

  8. Rao PV, Deng PF, Kumar J, Epstein DL (2001) Modulation of aqueous humor outflow facility by the rho kinase-specific inhibitor Y-27632. Invest Ophthalmol Vis Sci 42:1029–1037

    CAS  PubMed  Google Scholar 

  9. Tian B, Kaufman PL, Volberg T, Gabelt BT, Geiger B (1998) H-7 disrupts the actin cytoskeleton and increases outflow facility. Arch Ophthalmol (Chicago, Ill : 1960) 116:633–643

    Article  CAS  Google Scholar 

  10. Tanihara H, Inoue T, Yamamoto T, Kuwayama Y, Abe H, Araie M (2013) Phase 1 clinical trials of a selective rho kinase inhibitor, K-115. JAMA Ophthalmol 131:1288–1295. doi:10.1001/jamaophthalmol.2013.323

    Article  CAS  PubMed  Google Scholar 

  11. Tanihara H, Inoue T, Yamamoto T, Kuwayama Y, Abe H, Araie M (2013) Phase 2 randomized clinical study of a rho kinase inhibitor, K-115, in primary open-angle glaucoma and ocular hypertension. Am J Ophthalmol 156:731–736. doi:10.1016/j.ajo.2013.05.016

    Article  CAS  PubMed  Google Scholar 

  12. Tanihara H, Inoue T, Yamamoto T, Kuwayama Y, Abe H, Fukushima A, Suganami H, Araie M (2016) One-year clinical evaluation of 0.4% ripasudil (K-115) in patients with open-angle glaucoma and ocular hypertension. Acta Ophthalmol 94:e26–e34. doi:10.1111/aos.12829

    Article  CAS  PubMed  Google Scholar 

  13. Tanihara H, Inoue T, Yamamoto T, Kuwayama Y, Abe H, Suganami H, Araie M (2015) Additive intraocular pressure-lowering effects of the rho kinase inhibitor Ripasudil (K-115) combined with Timolol or Latanoprost: a report of 2 randomized clinical trials. JAMA Ophthalmol 133:755–761. doi:10.1001/jamaophthalmol.2015.0525

    Article  PubMed  Google Scholar 

  14. Inazaki H, Kobayashi S, Anzai Y, Satoh H, Sato S, Inoue M, Yamane S, Kadonosono K (2017) Efficacy of the additional use of Ripasudil, a rho-kinase inhibitor, in patients with glaucoma inadequately controlled under maximum medical therapy. J Glaucoma 26:96–100. doi:10.1097/ijg.0000000000000552

    PubMed  Google Scholar 

  15. Anderson DR, Patella VM (1999) Automated static Perimetry Mosby, St. Louis

  16. Omichi KWY, Yoneyama S (2014) Nonclinical safety assessment for the sensitizing potential of K-115. Fund Toxicol Sci 1:19–24

    Article  CAS  Google Scholar 

  17. Kashiwagi K, Tsumura T, Tsukahara S (2008) Long-term effects of latanoprost monotherapy on intraocular pressure in Japanese glaucoma patients. J Glaucoma 17:662–666. doi:10.1097/IJG.0b013e318166656d

    Article  PubMed  Google Scholar 

  18. Kashiwagi K, Furuya T (2014) Persistence with topical glaucoma therapy among newly diagnosed Japanese patients. Jpn J Ophthalmol 58:68–74. doi:10.1007/s10384-013-0284-2

    Article  PubMed  Google Scholar 

  19. Hahn SR, Kotak S, Tan J, Kim E (2010) Physicians’ treatment decisions, patient persistence, and interruptions in the continuous use of prostaglandin therapy in glaucoma. Curr Med Res Opin 26:957–963. doi:10.1185/03007991003659012

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Ophthalmology and Micro-technology, Yokohama City University School of Medicine, 4-57 Urafune-cho, Minami-ku, Yokohama, Kanagawa, 232-0024, Japan

    Hiroshi Inazaki, Satoshi Kobayashi, Yoko Anzai, Hisayoshi Satoh, Shimpei Sato, Maiko Inoue, Shin Yamane & Kazuaki Kadonosono

Authors
  1. Hiroshi Inazaki
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Satoshi Kobayashi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yoko Anzai
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Hisayoshi Satoh
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Shimpei Sato
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Maiko Inoue
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Shin Yamane
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Kazuaki Kadonosono
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hiroshi Inazaki.

Ethics declarations

Funding

No funding was received for this research.

Conflicts of interest

All authors certify that they have no affiliations with or involvement in any organization or entity with any financial interest (such as honoraria; educational grants; participation in speakers’ bureaus; membership, employment, consultancies, stock ownership, or other equity interest; or expert testimony or patent-licensing arrangements), or non-financial interest (such as personal or professional relationships, affiliations, knowledge or beliefs) in the subject matter or materials discussed in this manuscript.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments, or with comparable ethical standards.

Informed consent

Informed consent was obtained from all individual participants included in the study.

Financial support

None.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Inazaki, H., Kobayashi, S., Anzai, Y. et al. One-year efficacy of adjunctive use of Ripasudil, a rho-kinase inhibitor, in patients with glaucoma inadequately controlled with maximum medical therapy. Graefes Arch Clin Exp Ophthalmol 255, 2009–2015 (2017). https://doi.org/10.1007/s00417-017-3727-5

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00417-017-3727-5

Keywords

Search

Navigation